| Lymphoma |
| Recruiting | 2b | 102 | Europe, Canada, US, RoW | DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan | ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC | Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | 10/24 | 04/25 | | |
RiVa, NCT03307746: A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma |
|
|
| Active, not recruiting | 2a | 26 | Europe | Varlilumab, Rituximab | University Hospital Southampton NHS Foundation Trust, University Hospital Plymouth NHS Trust, The Christie NHS Foundation Trust, Oxford University Hospitals NHS Trust, Celldex Therapeutics, Cancer Research UK | B Cell Lymphoma | 02/21 | 03/24 | | |
CTR20221615: A single-arm, multicenter, open-label study to evaluate the efficacy and safety of FKC889 in adult patients with relapsed/refractory MCL |
|
|
| Not yet recruiting | 2 | 27 | China | Tecartus (brexucabtagene autoleucel) - Gilead | Fosun Kate Biotechnology Co., Ltd. | Adult patients with relapsed/refractory MCL;Mantle cell lymphoma | | | | |
CTR20220025: A single-arm, multicenter, open-label clinical study to evaluate the efficacy of FKC876 in adult patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) |
|
|
| Recruiting | 2 | 32 | China | Yescarta (axicabtagene ciloleucel) - Gilead | Fosun Kate Biotechnology Co., Ltd. | Relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) | | | | |
2011-001356-10: STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL). |
|
|
| Ongoing | 2 | 70 | Europe | Lenalidomide, Capsule, Revlimid (lenalidomide) | LYSARC, Celgene | Angioimmunoblastic T-cell Lymphoma (AITL), T lymphoma, Diseases [C] - Cancer [C04] | | | | |
2012-001597-29: Tumor uptake of ofatumumab and rituximab, labeled with 89Zirconium, in patients with malignant lymphoma. Tumor opname van ofatumumab en rituximab, gelabeld met 89Zirconium bij patienten met lymfeklierkanker |
|
|
| Ongoing | 2 | 45 | Europe | rituximab-N-succinyl-desferal-zirconium-89, ofatumumab-N-succinyl-desferal-zirconium-89, 89Zr-rituximab, 89Zr-ofatumumab, Solution for injection/infusion | VU University Medical Center, VU University Medical Center, GlaxoSmithKline | Diffuse large B cell lymphoma (DLBCL), lymphoma, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT00101101: Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma |
|
|
| Completed | 2 | 43 | US | Cyclophosphamide, Cytoxan, Doxorubicin, adriamycin, Rubex, Vincristine, Oncovin, leurocristine, VCR, Prednisone, Deltasone, Liquid Pred, Meticorten, Orasone, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Autologous Tumor Cell-Based Vaccine, IL-2, interleukin-2, cytokine, aldesleukin | H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI), Lymphoma Research Foundation, Novartis | Lymphoma | 10/12 | 06/21 | | |
2011-005562-38: Safety and Efficacy of peripheral blood stem cell transplantation using specifically purified stem cell preparations derived from patient family members in paediatric and adult patients Sicherheit und Wirksamkeit der Blutstammzelltransplantation mit spezifisch aufgereinigten Stammzellpräparaten von Famililienmitgliedern der Patienten als Spender bei Kindern und Erwachsenen |
|
|
| Ongoing | 2 | 60 | Europe | TCRabCD19PBSC, TCRabCD19PBSC_cryo, Suspension for injection | Miltenyi Biotec GmbH, Miltenyi Biotec GmbH | Hematological and non-hematological malignancies, and non-malignant diseases, requiring allogeneic blood stem cell transplantation without available HLA-identical donor. Hämatologische oder nicht-hämatologische maligne Erkrankungen oder nicht bösartige Erkrankungen, die einer allogenen Blutstammzelltransplantation eines haploidentischen Spenders bedürfen., Severe diseases requiring allogenic blood stem cell transplantation. Schwere Erkrankungen, die einer allogenen Blutstammzelltransplantation bedürfen., Diseases [C] - Cancer [C04] | | | | |
2012-005338-13: Treatment with Ofatumumab and Bendamustine in patients with lymphoma resistant to previous therapies Trattamento con Ofatumumab e Bendamustina in pazienti con linfoma resistente alle precedenti terapie |
|
|
| Ongoing | 2 | 73 | Europe | Bendamustine, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Arzerra | Istituto Clinico Humanitas - Humanitas Cancer Center, Regione Lombardia, GlaxoSmithKline | Non-Hodgkin's Follicular and Non-Follicular indolent lymphomas, relapsed/refractory Linfomi non Hodgkin indolenti follicolari e non follicolari, recidivati/refrattari, Indolent Lymphoma Linfomi indolenti, Diseases [C] - Cancer [C04] | | | | |
CALGB-50403, NCT00310037: Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 151 | US | bortezomib | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc. | Mantle Cell Lymphoma | 12/13 | | | |
|
NCT00644189: Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma |
|
|
| Completed | 2 | 50 | US | Clofarabine, Clolar | Massachusetts General Hospital, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Genzyme, a Sanofi Company | Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Low Grade B-cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large-cell Lymphoma | 12/13 | 07/21 | | |
NCT01472562: Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma |
|
|
| Completed | 2 | 38 | US | lenalidomide, revlimid, rituximab, rituxan | Weill Medical College of Cornell University, Celgene | Mantle Cell Lymphoma | 04/14 | 07/23 | | |
|
2013-005240-28: OPEN LABEL, PHASE IIA MULTICENTER STUDY OF DASATINIB IN THE TREATMENT OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL) RELAPSED/REFRACTORY OR NOT AMENABLE TO CONVENTIONAL THERAPY-PTCL-DASA01 Studio di fase IIa in aperto, multicentrico sul ruolo di dasatinib nel trattamento di pazienti con linfoma a cellule T periferiche (PTCL) ricaduto/refrattario o non candidabile a terapia convenzionale |
|
|
| Ongoing | 2 | 26 | Europe | Tablet | AOU di Bologna, Policlinico S.Orsola-Malpighi, Bristol-Myers-Squibb S.r.l. | PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL) pazienti con linfoma a cellule T periferiche (PTCL), PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL) pazienti con linfoma a cellule T periferiche (PTCL), Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
NCT01199575: Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) |
|
|
| Completed | 2 | 30 | US | Revlimid, lenalidomide, Rituximab, Rituxan | University of California, San Diego, Celgene Corporation | Chronic Lymphocytic Leukemia, CLL | 01/15 | 02/22 | | |
2014-005069-60: R-CPOP (Rituximab plus Cyclophosphamid, Pixantron, Vincristin, Prednison) as first line therapy for elderly patients with diffuse-large B cell lymphoma (DLBCL) and for patients with limited cardiac function with DLBCL R-CPOP (Rituximab plus Cyclophosphamid, Pixantron, Vincristin, Prednison) als Erstlinientherapie für ältere Patienten mit diffus großzelligem B-Zell-Lymphom (DLBCL) und für Patienten mit eingeschränkter Herzfunktion mit DLBCL |
|
|
| Ongoing | 2 | 60 | Europe | Powder for concentrate for solution for infusion, Pixuvri® | Medical Center - University of Freiburg, Servier Affaires Médicales, CTI Life Sciences Limited | Diffuse-large B cell lymphoma (DLBCL), A subtype of non-Hodgkin lymphoma, a tumour disease involving B lymphocytes, a particular type of white blood cells with a key role in immune system, Diseases [C] - Cancer [C04] | | | | |
NCT01361711: Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 2 | 53 | Europe, US | alemtuzumab, anti-CD52 monoclonal antibody, Campath-1H, MoAb CD52, Monoclonal Antibody Campath-1H, Monoclonal Antibody CD52, ofatumumab, Arzerra, HuMax-CD20, biopsy, biopsies | Northwestern University, GlaxoSmithKline, National Comprehensive Cancer Network | Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia | 08/15 | 05/27 | | |
| Completed | 2 | 28 | Europe | Abemaciclib, LY2835219 | Eli Lilly and Company | Mantle Cell Lymphoma | 09/15 | 09/22 | | |
|
2004-001563-21: A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström\'s Macroglobulinemia |
|
|
| Ongoing | 2 | 53 | Europe | epratuzumab, IMMU-103, | Immunomedics, Inc. | Waldenström\'s Macroglobulinemia (WM) is an uncommon B-cell lymphoproliferative disorder that predominantly involves older patients with a slight male preponderance. WM resembles myeloma and chronic lymphocytic leukemia, but has been described as a low-grade lymphoplasmacytic lymphoma characterized by its over production of monoclonal immunoglobulin M (IgM). | | | | |
2015-003318-26: Phase II, open-label, not comparative, multicenter study of multiple doses of NEPA (Netupitant+Palonosetron) in preventing chemotherapy induced nausea and vomiting(CINV) in patient with Non Hodgkin’s Lymphomareceiving salvage chemotherapy followed by high dose chemotherapy and autologous hematopoietic stem cells support. Studio di fase II, in aperto, non comparativo, multicentrico, di dosi ripetute di NEPA (netupitant + palonosetron) nella prevenzione della nausea ed il vomito indotti da chemioterapia (CINV) in pazienti con Linfoma Non-Hodgkin trattati con chemioterapia di salvataggio seguita da alte dosi di chemioterapia con supporto di cellule staminali ematopoietiche |
|
|
| Ongoing | 2 | 81 | Europe | AKYNZEO, EU/1/15/1001/001, Capsule, hard, AKYNZEO | ASSOCIAZIONE SALENTINA ANGELA SERRA ONLUS, ITALFARMACO S.P.A. | NON HODGKIN'S LYMPHOMA LINFOMA NON HODGKIN, NON HODGKIN'S LYMPHOMA LINFOMA NON HODGKIN, Diseases [C] - Cancer [C04] | | | | |
NCT01027000: Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
|
|
| Completed | 2 | 68 | US | rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, sirolimus, tacrolimus, allogeneic stem cell transplant | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Genentech, Inc., Biologics, Inc. | Leukemia, Lymphoma | 01/16 | 04/23 | | |
2015-005273-20: Multicenter phase II single arm open-label study on the feasibility, safety and efficacy of combination of CHOP-21 supplemented with Obinutuzumab and Ibrutinib in untreated young high risk Diffuse Large B-cell Lymphoma (DLBCL) patients. Studio multicentrico di fase II a braccio singolo sulla fattibilit¿, sicurezza ed efficacia della combinazione CHOP-21 con Obinutuzumab e Ibrutinib come terapia di prima linea in pazienti giovani ad alto rischio affetti da linfoma a grandi cellule B. |
|
|
| Not yet recruiting | 2 | 90 | Europe | Imbruvica, Ibrutinib, Concentrate for solution for infusion, Capsule, hard, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO, IMBRUVICA - 140 MG -CAPSULE RIGIDE -USO ORALE - FLACONE (HDPE) - 1 FLACONE (90 CAPSULE RIGIDE) | FONDAZIONE ITALIANA LINFOMI ONLUS, Roche, Janssen - Cilag | Diffuse Large B-Cell lymphoma (DLBCL) Linfoma a grandi cellule B (DLBCL), Diffuse Large B-Cell lymphoma Linfoma a grandi cellule B, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2015-003820-30: A CLINICAL STUDY TO EXPLORE THE EFFICACY, SAFETY AND TOLERABILITY OF DEUTERIUM DEPLETED WATER IN PREVIOUSLY UNTREATED PATIENTS WITH ASYMPTOMATIC CHRONIC LYMPHOCYTIC LEUKEMIA. |
|
|
| Ongoing | 2 | 25 | Europe | Depletin, Oral liquid | HYD Pharma Zrt., HYD Pharma Zrt. | Previously untreated patients with asymptomatic chronic lymphocytic leukemia but who are at high risk of progression., Previously untreated patients with asymptomatic chronic lymphocytic leukemia but who are at high risk of progression., Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2015-001814-85: Brighton: PNT2258 for Treatment of Patients with Richter's Transformation |
|
|
| Ongoing | 2 | 49 | Europe | PNT2258, Dispersion for infusion | ProNAi Therapeutics, Inc., ProNAi Therapeutics, Inc. | Diffuse large B-cell non-Hodgkin's lymphoma with Richter's Transformation (RT) from chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Richter’s Transformation, Diseases [C] - Cancer [C04] | | | | |
PRECIS, NCT00863460: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients |
|
|
| Active, not recruiting | 2 | 140 | Europe | cranial radiotherapy, intensive chemotherapy and hematopoietic stem cell rescue, Thiotepa IV (250 mg/m²/day) day-9 day-8 day-7, Busulfan IV (0.8 mg/kg X 10) day-6 to day-4, Cyclophosphamide IV (60 mg/kg/day) day-3 & day-2, Reinjection of hematopoietic stem cells day0, MTX based chemotherapy, R-RMVP :, Rituximab IV if LNH type B (375 mg/m²) day1, Methotrexate IV (3g/m² during 30 minutes) day1 and day15, Etoposide IV (100 mg/m²) day2, Carmustine IV (100 mg/m²) day3, Prednisone PO (60 mg/m²/day)day1 to day5, R-Aracytine :, Aracytine IV (3g/m²) day1 & day2 | Institut Curie, Ministry of Health, France, Hoffmann-La Roche, Amgen, Pierre Fabre Laboratories | Primary Central Nervous System Lymphoma | 05/16 | 05/26 | | |
| Completed | 2 | 227 | Europe, Canada, US, RoW | Copanlisib (Aliqopa, BAY80-6946) | Bayer | Lymphoma, Non-Hodgkin | 06/16 | 05/23 | | |
|
|
|
2016-001033-27: REMODEL - WM3 An Open Label non-randomized Phase II Study exploring «chemo-free » treatment association with Idelalisib + Obinutuzumab in Patient with relapsed/refractory Waldenstrom’s Macroglobulinemia (MW) REMODEL - WM3 Etude ouverte de phase II évaluant l’efficacité d’un traitement «sans chimiothérapie » par l’association de l’Idelalisib avec l’Obinutuzumab chez les patients atteints de la Maladie de Waldenström (MW) |
|
|
| Ongoing | 2 | 50 | Europe | Obinutuzumab, R05072759/F06-01, Concentrate for solution for infusion, Film-coated tablet, Gazyvaro, Zydelig | FILO, Roche, GILEAD | Waldenstrom’s Macroglobulinemia (MW) Macroglobulinémie de Waldenstrom (MW), Patient with relapsed/refractory Waldenstrom’s Macroglobulinemia Patient en rechute ou réfractaire d'une macroglobulinémie de Waldenstrom, Diseases [C] - Cancer [C04] | | | | |
2015-003371-29: Phase II study. A combination of Lenalidomide and Rituximab as front line therapy for elderly frail patients (CGA) with Diffuse Large B-cells non-Hodgkin Lymphoma. Studio di fase II per valutare la combinazione di Lenalidomide e Rituximab in prima linea nei pazienti anziani con linfoma diffuso a grandi cellule B classificati fragili (CGA) |
|
|
| Not yet recruiting | 2 | 68 | Europe | Revlimid 5 mg, Revlimid 10 mg, Revlimid 15 mg, Revlimid 20 mg, [IMP1], [IMP2], [IMP3], [IMP4], Capsule, hard, REVLIMID - 5 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CASPULE, REVLIMID - 10 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE, REVLIMID - 15 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE, REVLIMID - 20 MG- CAPSULA RIGIDA- USO ORALE- BLISTER (PCTFE/PVC/ALU)- 21 CAPSULE | FONDAZIONE ITALIANA LINFOMI ONLUS, Celgene | Diffuse Large B-cells non-Hodgkin Lymphoma Linfoma diffuso a grandi cellule B, Elderly frail patients with Diffuse Large B-cells non-Hodgkin Lymphoma. Pazienti anziani con linfoma diffuso a grandi cellule B classificati fragili, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2015-004985-27: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens |
|
|
| Ongoing | 2 | 70 | Europe | obinutuzumab, venetoclax 10 mg, venetoclax 50mg, venetoclax 100mg, Concentrate for solution for infusion, Tablet, Gazyvaro | HOVON Foundation, Dutch Cancer Society, Roche | Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04] | | | | |
2016-004707-32: Clinical trial with Ibrutinib and Venetoclax for patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Studio Clinico con Ibrutinib e Venetoclax per pazienti con Leucemia Linfatica Cronica Recidivante o Refrattaria |
|
|
| Ongoing | 2 | 31 | Europe | VENETOCLAX, [ABT-199], Film-coated tablet | OSPEDALE SAN RAFFAELE, Abbvie | Relapsed or Refractory Chronic Lymphocytic Leukemia Leucemia Linfatica Cronica Recidivante o Refrattaria, Chronic Lymphocytic Leukemia relapsed or refractory to previous treatments Leucemia Linfatica Cronica ricaduta o non responsiva ai trattamenti precedenti, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2016-002599-29: A trial evaluating treatment with ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) |
|
|
| Ongoing | 2 | 230 | Europe | venetoclax 10 mg, venetoclax 50 mg, venetoclax 100 mg, ibrutinib, Tablet, Capsule, hard, Venclyxto, Imbruvica | HOVON Foundation, AbbVie, Janssen | Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04] | | | | |
2016-003970-41: Clinical trial with the drug lorlatinib in patients affected by a lymphoma that expresses the protein ALK, previously treated with ALK inhibitors but for whom the therapy is not anymore effective Sperimentazione clinica con il farmaco lorlatinib in pazienti affetti da linfoma che esprime la proteina ALK, che sono stati precedentemente trattati con altri farmaci contro ALK ma che non rispondono più alla terapia |
|
|
| Ongoing | 2 | 12 | Europe | PF-06463922, [lorlatinib], Tablet | UNIVERSITÀ DEGLI STUDI MILANO BICOCCA, Pfizer | Anaplastic Large Cells Lymphoma (ALCL) ALK+ Linfoma anaplastico a grandi cellule (ALCL) ALK +, ALCL is a lymphoma associated with the formation of the protein NPM-ALK that determines the abnormal production of white cells ALCL è un linfoma associato alla formazione della proteina NPM-ALK che determina una produzione anomala di globuli bianchi., Diseases [C] - Cancer [C04] | | | | |
NCT01145209: Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL |
|
|
| Completed | 2 | 32 | US | Fludarabine Phosphate, Fludara, Ofatumumab, Arzerra, Cyclophosphamide, Cytoxan, Neosar | National Heart, Lung, and Blood Institute (NHLBI), University of Virginia, GlaxoSmithKline | Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia) | 10/17 | 09/23 | | |
| Completed | 2 | 582 | Europe | Crizotinib (PF-02341066) | European Organisation for Research and Treatment of Cancer - EORTC, Pfizer | Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1, Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma, Locally Advanced and/or Metastatic Clear Cell Sarcoma, Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma | 12/17 | 10/22 | | |
|
|
| Active, not recruiting | 2 | 92 | Europe | Gemcitabine, Methylprednisolone, Rituximab, Cisplatin, Lenalidomide | Royal Marsden NHS Foundation Trust, Celgene Corporation | Diffuse Large B-Cell Lymphoma | 02/18 | 08/23 | | |
2017-002544-32: A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma fit for autologous stem cell transplant who fail to reach complete metabolic remission after first or second line salvage therapy |
|
|
| Not yet recruiting | 2 | 120 | Europe | Opdivo, BMS-936558, Concentrate for solution for infusion, Opdivo | University College London, Bristol-Myers Squibb Pharmaceuticals Ltd | Relapsed/refractory Hodgkin lymphoma, Hodgkin lymphoma is a cancer of the lymphatic system due to abnormal lymphocytes. Refractory means not responding to initial treatment. Relapse is where disease returns after initial response., Diseases [C] - Cancer [C04] | | | | |
2017-003256-22: Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) In Younger, High-Risk Patients with Diffuse Large B-Cell Lymphoma Ibrutinib und Standard-Immunochemotherapie (R-CHOEP-14) in jungen Hochrisiko- Patienten mit diffusem großzelligem B-Zell-Lymphom |
|
|
| Not yet recruiting | 2 | 40 | Europe | Capsule, hard, IMBRUVICA 140 mg hard capsules | Universitätsklinikum Münster, Janssen-Cilag GmbH | diffuse large B-cell lymphoma diffuses großzelliges B-Zell-Lymphom, malignant disease of the lymphatic system bösartige Erkrankung des lymphatischen Systems, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT02639559: Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies |
|
|
| Completed | 2 | 50 | US | BL-8040, Leukapheresis, Hematopoietic cell transplant | Washington University School of Medicine, BioLineRx, Ltd. | Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease, Hodgkins Disease, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm | 04/18 | 04/23 | | |
2017-004628-31: Venetoclax after chemotherapy R-BAC in high-risk elderly patients with mantle cell lymphoma Venetoclax dopo chemioterapia R-BAC in pazienti anziani affetti da linfoma mantellare |
|
|
| Not yet recruiting | 2 | 130 | Europe | Venclyxto, Film-coated tablet, Venclyxto | Fondazione Italiana Linfomi ONLUS, AbbVie S.r.l. | Mantle Cell Lymphoma in elderly patients Linfoma mantellare in pazienti anziani, Mantle Cell Lymphoma in elderly patients Linfoma mantellare in pazienti anziani, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2017-001099-49: therapy with ibrutinib for patients with Chronic lymphocytic leukemia with subclonal TP53 aberrations terapia con Ibrutinib per pazienti affetti da leucemia linfatica cronica che presentano alterazioni subclonali di TP53 |
|
|
| Ongoing | 2 | 185 | Europe | ibrutinib, [PCI-32765], Capsule, hard | OSPEDALE SAN RAFFAELE, Janssen-Cilag International N.V., Belgium | Chronic Lymphocytic Leukemia (CLL) leucemia linfatica cronica (LLC), Chronic Lymphocytic Leukemia never treated leucemia linfatica cronica mai trattata, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 59 | RoW | Bortezomib, velcade | Samsung Medical Center, Janssen, LP | Diffuse Large B Cell Lymphoma | 10/18 | 10/21 | | |
2017-004401-40: A trial of CHOP-R therapy with or without acalabrutinib in patients with newly diagnosed Richter's Syndrome |
|
|
| Not yet recruiting | 2 | 105 | Europe | Cyclophosphamide, Acalabrutinib, Doxorubicin, Vincristine, Prednisolone, Rituximab, ACP-196, Powder and solvent for solution for injection/infusion, Capsule, hard, Concentrate and solvent for solution for infusion, Solution for injection, Tablet, Solution for infusion, Cyclophosphamide, Acalabrutinib, Vincristine, Prednisolone, Rituximab | University of Birmingham, Bloodwise, Acerta | Richter's Syndrome, A rare type of non-hodgkin lymphoma, Diseases [C] - Cancer [C04] | | | | |
2017-005137-23: Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with (ABC) DLBCLat intermediate-high and high risk Terapia R-CHOP in combinazione con ibrutinib e successivo mantenimento con ibrutinib in pazienti non trattati con linfoma diffuso a grandi cellule B con profilo ABC e rischio intermedio/alto o alto. |
|
|
| Not yet recruiting | 2 | 90 | Europe | Ibrutinib, IMP1, Capsule, hard, IMBRUVICA - 140 MG -CAPSULE RIGIDE -USO ORALE - FLACONE (HDPE) - 1 FLACONE (120 CAPSULE RIGIDE) | FONDAZIONE ITALIANA LINFOMI ONLUS, Janssen-Cilag S.p.A | Activated-B-Cell Lymphoma (ABC)-DLBCLat intermediate-high and high risk (IPI =2) Linfoma diffuso a grandi cellule B con profilo ABC (Activated-B-Cell) e rischio intermedio/alto o alto (IPI = 2), B-Cell Lymphoma (ABC)-DLBCLat intermediate-high and high risk Linfoma diffuso a grandi cellule B con profilo ABC e rischio intermedio/alto o alto, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2018-002227-42: Avelumab in the frontline treatment of advanced classical Hodgkin lymphoma - a window study |
|
|
| Not yet recruiting | 2 | 47 | Europe | Avelumab, MSB0010718C, Concentrate for solution for infusion, Avelumab | University College London, Pfizer Limited | Advanced classical Hodgkin lymphoma, Advanced classical Hodgkin lymphoma is a cancer that causes the lymphocytes (a type of white blood cell involved in fighting infections) to grow abnormally., Diseases [C] - Cancer [C04] | | | | |
2017-003334-82: Effect of Radiotherapy and Nivolumab in Relapsed classical Hodgkin Lymphoma Effekt von Radiotherapie und Nivolumab bei rezidiviertem klassischen Hodgkin Lymphom |
|
|
| Not yet recruiting | 2 | 29 | Europe | Nivolumab, Lyophilisate for solution for infusion, Opdivo | University of Cologne, Bristol-Myers Squibb, GHSG | Improvement of efficacy of nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma who recently progressed on anti-PD1 therapy., Improvement of efficacy of nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma who recently progressed on anti-PD1 therapy., Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 2 | 30 | Europe | Obinutuzumab 25 MG/ML, Gazyvaro | Polish Myeloma Consortium, Roche Pharma AG, Bioscience, S.A. | Waldenstrom Macroglobulinemia | 04/19 | 12/22 | | |
NU 16H08, NCT03226249: PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma |
|
|
| Active, not recruiting | 2 | 30 | US | Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, computerized tomography, CT, CT SCAN, tomography, Dacarbazine, 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Fludeoxyglucose F-18, 18FDG, FDG, fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Vinblastine Sulfate, 29060 LE, 29060-LE, Exal, Velban, Velbe, Velsar, VINCALEUKOBLASTINE | Northwestern University, National Cancer Institute (NCI), Merck Sharp & Dohme LLC | Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma, Lymphocyte-Rich Classical Hodgkin Lymphoma, Mixed Cellularity Classical Hodgkin Lymphoma, Nodular Sclerosis Classical Hodgkin Lymphoma | 05/19 | 10/24 | | |
2018-000873-59: A trial to improve disease control after an allogeneic stem cell transplantation for relapsed or refractory classical Hodgkin lymphoma with consolidation therapy by Brentuximab Vedotin |
|
|
| Not yet recruiting | 2 | 21 | Europe | Adcetris, Lyophilisate for solution for infusion, Adcetris | University of Cologne, Takeda Pharmaceutical Company Ltd. | disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation therapy by Brentuximab Vedotin (BV), Diseases [C] - Cancer [C04] | | | | |
2018-001229-18: Idelalisib (I) in combination with Obinutuzumab (G) for the treatment of patients with relapsed / refractory follicular lymphoma: multicentric phase II single arm study. Idelalisib (I) in combinazione con Obinutuzumab (G) per il trattamento di pazienti con linfoma follicolare ricaduto/refrattario: studio multicentrico di fase II a braccio singolo. |
|
|
| Not yet recruiting | 2 | 43 | Europe | Zydelig, GAZYVARO, [IMP1], [Obinutuzumab], Capsule, hard, Concentrate for solution for infusion, Zydelig, Gazyvaro | FONDAZIONE ITALIANA LINFOMI ONLUS, GILEAD, ROCHE | recurrent / refractory follicular lymphoma linfoma follicolare ricaduto/refrattario, recurrent / refractory follicular lymphoma linfoma follicolare ricaduto/refrattario, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2018-000540-25: Carfilzomib + Lenalidomide +Dexamethasone for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas Terapia di salvataggio ( Carfilzomib + Lenalidomide +Desametasone) per linfomi mantellari ricaduti, refrattari o intolleranti a trattamento con inibitori di BTK |
|
|
| Not yet recruiting | 2 | 59 | Europe | REVLIMID/LENALIDOMIDE, KRYPOLIS, [IMP1 - 5 MG], [IMP2], [IMP3- 10 MG], [IMP4 - 25 MG], Capsule, hard, Powder for solution for infusion, REVLIMID, KYPROLIS, REVLIMID - 15 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE | FONDAZIONE ITALIANA LINFOMI ONLUS, CELGENE, AMGEN | BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas Linfomi mantellari ricaduti, refrattari o intolleranti a trattamento con inibitori di BTK, BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas Linfomi mantellari ricaduti, refrattari o intolleranti a trattamento con inibitori di BTK, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Completed | 2 | 105 | Europe, US | brexucabtagene autoleucel, KTE-X19, TECARTUS™, Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel | Kite, A Gilead Company | Relapsed/Refractory Mantle Cell Lymphoma | 07/19 | 09/23 | | |
|
|
|
|
2014-001911-38: AN PHASE II STUDY OF EFFICACY AND TOXICITY OF MAINTENANCE SUBCUTANEOUS RITUXIMAB AFTER RESCUE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA NON-ELIGIBLE FOR AUTO OR ALLO STEM CELL TRANSPLANTATION. Estudio fase II para evaluar la eficacia y toxicidad de la terapia de mantenimiento con rituximab tras el tratamiento de rescate en pacientes con linfoma de células del manto recurrente o refractario no candidatos a trasplante autológo o Alogénico |
|
|
| Not yet recruiting | 2 | 17 | Europe | Rituximab, Rituximab, Concentrate for solution for injection, MabThera subcutaneo | Grupo Español de Linfoma y Trasplante Autólogo de Médula ósea, Roche farma | PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA NON-ELIGIBLE FOR AUTO OR ALLO STEM CELL TRANSPLANTATION PACIENTES CON LINFOMA DE CÉLULAS DEL MANTO RECURRENTE O REFRACTARIO NO CANDIDATOS A TRANSPLANTE AUTOLÓGO O ALOGÉNICO DE PROGENITORES HEMATOPOYÉTICOS?, MANTLE-CELL LYMPHOMA Linfoma de Células del Manto, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Active, not recruiting | 2 | 107 | Europe, US | Acalabrutinib (ACP-196), Acalabrutinib | Acerta Pharma BV | Waldenström Macroglobulinemia (WM) | 10/19 | 12/26 | | |
|
|
| Active, not recruiting | 2 | 50 | Europe | IBRUTINIB, Imbruvica, Rituximab | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Janssen-Cilag, S.A. | Mantle Cell Lymphoma | 12/19 | 12/24 | | |
| Completed | 2 | 13 | US | Blinatumomab, Blincyto | Massachusetts General Hospital, Amgen | Non-Hodgkin Lymphoma | 01/20 | 12/23 | | |
2018-002364-44: Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomas |
|
|
| Ongoing | 2 | 175 | Europe | MabThera Uso sottocutaneo, MabThera, Imbruvica, [NA], Solution for injection, Concentrate for solution for infusion, Capsule, hard, MabThera, Imbruvica | IELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP, Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV | Previously untreated and symptomatic patients with histologically proven CD20-positive marginal zone B-cell lymphoma (MZL) in need of systemic treatment, Previously untreated marginal zone lymphoma, Diseases [C] - Cancer [C04] | | | | |
2018-003560-31: Copanlisib and Standard Immuno-Chemotherapy (R-CHOP) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Copanlisib und Standard-Immunochemotherapie (R-CHOP) in Patienten mit diffusem großzelligem B-Zell-Lymphom (DLBCL) |
|
|
| Ongoing | 2 | 80 | Europe | Copanlisib, BAY84-1236, Lyophilisate for solution for infusion | Universitätsklinikum Münster, Bayer HealthCare Pharmaceuticals Inc. | diffuse large B-cell lymphoma diffuses großzelliges B-Zell-Lymphom, malignant disease of the lymphatic system bösartige Erkrankung des lymphatischen Systems, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2019-003131-31: Ravagalimab Vs Placebo in Subjects with Moderately to Severely Active Primary Sjogren's Syndrome |
|
|
| Not yet recruiting | 2 | 45 | Europe | Ravagalimab, ABBV-323, Powder for concentrate for solution for injection/infusion | AbbVie Deutschland GmbH & Co. KG, AbbVie Inc. | Moderately to Severely Active Primary Sjogren's Syndrome, An autoimmune disease affecting the entire body; symptoms include dry mouth, and serious complications such as profound fatigue, chronic pain, major organ involvement, neuropathies and lymphomas., Diseases [C] - Immune System Diseases [C20] | | | | |
NCT03623373: Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 13 | US | Bendamustine, Treanda, Bendeka, Rituximab, Rituxan, Rituxan Hycela, Acalabrutinib, Calquence®, Cytarabine, Cytosar-U, Leukapheresis, Peripheral blood, Oral rinse, Bone marrow collection | Washington University School of Medicine, Acerta Pharma BV | Mantle Cell Lymphoma | 02/20 | 02/25 | | |
2018-002644-91: Clinical trial with Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin in patients with relapsed/refractory CD38 positive peripheral T-cell lymphoma Sperimentazione clinica con Daratumumab in combinazione con gemcitabina, desametasone e cisplatino per il trattamento di pazienti con linfoma a cellule T periferico CD38 positivo ricaduto/refrattario |
|
|
| Not yet recruiting | 2 | 35 | Europe | Darzalex, Desametasone, Gemcitabina, Cisplatino, [IMP1], [IMP2], [IMP4], [IMP3], [IMP5], Concentrate for solution for infusion, Concentrate for solution for injection, DARZALEX - 20 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO)- 20 ML- 1 FLACONCINO, DARZALEX - 20 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO)- 5 ML- 1 FLACONCINO, DECADRON - 4 MG/1 ML SOLUZIONE INIETTABILE 3 FIALE DA 1 ML, GEMCITABINA ACCORD - 100 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 10 ML, CISPLATINO ACCORD HEALTHCARE ITALIA - 1MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 10 ML | FONDAZIONE ITALIANA LINFOMI ONLUS, Janssen | Relapsed/refractory CD38 positive peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of TFH cell origin Linfoma a cellule T periferico CD38 positivo ricaduto/refrattario di tipo non ulteriormente specificato (PTCL-NOS), angioimmunoblastico (AITL) e con fenotipo T-follicular helper (TFH), Relapsed/refractory CD38 positive peripheral T-cell lymphoma Linfoma a cellule T periferico CD38 positivo ricaduto/refrattario, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT03542266: CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma |
|
|
| Completed | 2 | 21 | US | CC-486 Administration, Oral Azacitidine, CHOP Administration | Weill Medical College of Cornell University, Celgene Corporation | Previously Untreated Peripheral T-cell Lymphoma | 03/20 | 07/22 | | |
2019-000842-36: Polatuzumab vedotin combined with standard chemo-immunotherapy drugs in diffuse large B-cell lymphoma |
|
|
| Not yet recruiting | 2 | 56 | Europe | Polatuzumab Vedotin, Lyophilisate for solution for infusion | The Clatterbridge Cancer Centre NHS Foundation Trust, Roche Products Ltd | Diffuse large B-cell lymphoma in patients with co-morbidities who cannot tolerate full dose R-CHOP., A cancer of the blood affecting B-cells., Diseases [C] - Cancer [C04] | | | | |
2019-002746-21: A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with ESHAP vsRandomized study to evaluate the efficacy of therapy with BrentuximabVedotin-Etoposide, Methylprednisolone, Cisplatin and Cytarabine (ESHAP)vs ESHAP in patients with Hodgkin's Lymphoma, followed by treatmentwith Brentuximab Vedotin in patients who reach metabolic response aftersalvage therapy Estudio aleatorizado para evaluar la eficacia de la terapia con Brentuximab Vedotin -Etopsido, Metilprednisolona, Cisplatino y Citarabina (ESHAP) vs ESHAP en pacientes con Linfoma de Hodgkin, seguido de tratamiento con Brentuximab Vedotin en pacientes que alcancen respuesta metablica tras la terapia de rescate |
|
|
| Ongoing | 2 | 150 | Europe, RoW | Powder for solution for infusion, Adcetris | Fundación GELTAMO, Grupo Español de linfomas y trasplante autologo de medula osea (GELTAMO), Takeda Pharmaceuticals | Patients with Relapsed /Refractory Classical Hodgkin's Lymphoma Pacientes con Linfoma de Hodgkin Clásico Refractario o en Recaída, Hodgkin’s Lymphoma Linfoma de Hodgkin, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Not yet recruiting | 2 | 25 | NA | DPX-Survivac, Pembrolizumab, Cyclophosphamide 50mg | Sunnybrook Health Sciences Centre, ImmunoVaccine Technologies, Inc., Merck Sharp & Dohme Corp. | Diffuse Large Cell Lymphoma, Recurrent, Adult, Refractory Diffuse Large B-Cell Lymphoma | 05/20 | 05/21 | | |
2015-003128-30: Ibrutinib in relapsed lymphocyte-predominant Hodgkin lymphoma Ibrutinib zur Behandlung des rezidivierten nodulär Lymphozyten-prädominanten Hodgkin Lymphom |
|
|
| Not yet recruiting | 2 | 36 | Europe | Capsule, hard, Imbruvica | University of Cologne, JANSSEN-CILAG GmbH | relapsed lymphocyte-predominant Hodgkin lymphoma rezidiviertes nodulär Lymphozyten-prädominantes Hodgkin Lymphom, relapsed Hodgkin lymphoma (cancer of lymphatic system) Rückfall eines Hodgkin Lymphoms (Krebserkrankung des lymphatischen Systems), Diseases [C] - Cancer [C04] | | | | |
2018-003270-27: Evaluation of a treatment with bendamustine, followed by obinutuzumab,zanubrutinib and venetoclax in patients with relapsed chronic lymphocyticleukemia |
|
|
| Not yet recruiting | 2 | 40 | Europe | Bendamustine, Obinutuzumab / GA101, ABT-199 (GDC-0199), Venetoclax, Zanubrutinib, RO5072759, BGB-3111, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tablet, Capsule, hard, Gazyvaro, Venclyxto (Venetoclax) | Universität zu Köln B.1.2, BeiGene Ltd., Roche Pharma AG | Patients with relapsed/refractory CLL requiring treatment, Patients with relapsed chronic lymphocytic leukaemia in need oftreatment, Diseases [C] - Cancer [C04] | | | | |
2019-003632-23: Lenalidomide and Ibrutinib in association with R-MPV first-line treatment of Primary Central Nervous System Lymphoma for patients aged 18 to 60 Lénalidomide et Ibrutinib en association avec le R-MPV en traitement d’induction de première ligne pour les patients âgés de 18 à 60 ans présentant un lymphome primitif du système nerveux central (LCP). |
|
|
| Not yet recruiting | 2 | 128 | Europe | Ibrutinib 140 mg, Rituximab, Methotrexate, Procarbazine, Vincristine, Prednisone, Capsule, hard, Solution for infusion, Capsule, Tablet, Revlimid 5 mg, Revlimid 10 mg, Imbruvica 140 mg | Institut Curie, PHRC-K 2018 Public Health Grant, CELGENE SAS, JANSSEN-CILAG, KEOCYT SAS | Primary Central Nervous System Lymphoma (PCNSL) in patients aged 18 to 60, in first-line treatment Lymphome primitif du système nerveux central chez des patients âgés de 18 à 60 ans, en traitement de première ligne, Primary Central Nervous System Lymphoma in patients aged 18 to 60, first treatment Lymphome primitif du système nerveux central chez des patients âgés de 18 à 60 ans, 1er traitement, Diseases [C] - Cancer [C04] | | | | |
2018-004038-13: Chemotherapy-free combination of Copanlisib withObinutuzumab (GA 101) in Patients with Previously Untreated FollicularLymphoma (FL) and High Tumor Burden |
|
|
| Not yet recruiting | 2 | 102 | Europe | Copanlisib, Obinutuzumab, BAY 80-6946, RO5072759/F06-01, Lyophilisate for solution for infusion, Concentrate for solution for infusion, Gazyvaro | Klinikum der Universität München, Bayer HealthCare Pharmaceuticals Inc., Roche Pharma AG | Follicular Lymphoma with high tumor burden (grade 1- 3a, Ann Arbour stage II - IV, previously untreated), Follicular Lymphoma with need of treatment, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
15-H-0016, NCT02337829: Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL |
|
|
| Active, not recruiting | 2 | 48 | US | Acalabrutinib (Arm A), ACP-196, Acalabrutinib (Arm B) | Acerta Pharma BV, National Institutes of Health (NIH) | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 06/20 | 04/26 | | |
|
|
2019-004337-17: Behandeling van chronische lymfatische leukemie met venetoclax en acalabrutinib bij terugkeer van de ziekte na eerdere behandeling met venetoclax in combinatie met immuuntherapie Retreatment of CLL with venetoclax and acalabrutinib after relapse after first line venetoclax treatment combined with immunotherapy for chronic lymphocytic leukemia (CLL or SLL) |
|
|
| Ongoing | 2 | 60 | Europe | venetoclax 10 mg, venetoclax 50 mg, venetoclax 100 mg, Acalabrutnib, Tablet, Capsule, hard, Venclyxto | HOVON Foundation, AbbVie B.V., AstraZeneca BV | Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 60 | Europe, US, RoW | ACP-196 (acalabrutinib), Acalabrutinib | Acerta Pharma BV | Chronic Lymphocytic Leukemia | 10/20 | 09/26 | | |
|
2018-000187-28: Efficacy of pembrolizumab in patients with marginal zone lymphoma |
|
|
| Not yet recruiting | 2 | 56 | Europe | Pembrolizumab, MK-3475, Solution for infusion, Concentrate for solution for infusion, KEYTRUDA (pembrolizumab, MK3475), Truxima | University Hospital Ulm, Universitätsklinikum Ulm, MSD SHARP & DOHME GMBH, Celltrion Healthcare Co., LTD | Marginal Zone Lymphoma, Marginal Zone Lymphoma, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 323 | Europe, US, RoW | ibrutinib, venetoclax, Placebo | Pharmacyclics LLC., Janssen Research & Development, LLC | Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 11/20 | 03/24 | | |
|
|
|
|
|
NCT01920932: Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma |
|
|
| Active, not recruiting | 2 | 77 | US | brentuximab vedotin, SGN-35, Adcetris(R), etoposide, VP-16, Vepesid(R), prednisone, prednisolone, doxorubicin, Adriamycin(R), cyclophosphamide, Cytoxan(R), Dacarbazine(R), Dimethyl Triazeno Imidazole Carboximide (DTIC), filgrastim, Neupogen(R), quality of life assessment, radiation therapy, irradiation, radiotherapy, radiation | St. Jude Children's Research Hospital, Seagen Inc. | Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma | 11/20 | 05/28 | | |
| Completed | 2 | 129 | Europe, Canada, US, RoW | Duvelisib, Copiktra, IPI-145 | SecuraBio | Indolent Non-Hodgkin Lymphoma | 11/20 | 11/20 | | |
|
|
|
|
|
|
|
|
|
|
| Active, not recruiting | 2 | 98 | Europe, Japan, US, RoW | tisagenlecleucel, CTL019 | Novartis Pharmaceuticals | Follicular Lymphoma | 11/20 | 05/25 | | |
|
|
|
|
|
|
|
2019-003983-28: A phase 2 study of retreatment with brentuximab vedotin in subjects with classic Hodgkin lymphoma or CD30-expressing peripheral T cell lymphoma Studio di fase 2 di ritrattamento con brentuximab vedotin in soggetti affetti da linfoma di Hodgkin classico o linfoma periferico a cellule T CD30-positivo |
|
|
| Not yet recruiting | 2 | 80 | Europe | Brentuximab vedotin, [SGN-35], Powder for concentrate for solution for infusion, ADCETRIS® | SEAGEN INC., Seattle Genetics, Inc. | - classic Hodgkin lymphoma (cHL)- Systemic anaplastic large cell lymphoma (sALCL)- CD30-expressing peripheral T cell lymphoma (PTCL) - linfoma di Hodgkin classico (cHL)- Linfoma anaplastico sistemico a grandi cellule (sALCL)- Linfoma a cellule T periferiche che esprimono CD30 (PTCL), - Hodgkin lymphoma- Lymphoma- T cell lymphoma - Linfoma di Hodgkin- Linfoma- Linfoma a cellule T, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 124 | Europe, US, RoW | ACP-196 (acalabrutinib) | Acerta Pharma BV | Mantle Cell Lymphoma (MCL) | 12/20 | 09/26 | | |
|
|
|
2019-002373-59: A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma. Eine Phase-II-Studie zur Untersuchung von Gemcitabin/Oxaliplatin/Rituximab mit Tafasitamab (MOR-00208) bei Patienten mit aggressivem Lymphom. |
|
|
| Ongoing | 2 | 64 | Europe | Tafasitamab, MOR00208, Lyophilisate for solution for infusion, MINJUVI® 200 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung | University Medical Center of the Johannes Gutenberg University Mainz, Incyte Corporation | Malignant B-cell lymphoma Aggressives B-Zell Lymphom, Malignant Lymphoma Aggressives Lymphom, Diseases [C] - Cancer [C04] | | | | |
NU 16H07, NCT03077828: Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
|
|
| Active, not recruiting | 2 | 43 | US | Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475 | Northwestern University, Merck Sharp & Dohme LLC, National Cancer Institute (NCI) | Lymphocyte-Rich Classical Hodgkin Lymphoma, Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma, Recurrent Mixed Cellularity Classical Hodgkin Lymphoma, Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma, Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma, Refractory Mixed Cellularity Classical Hodgkin Lymphoma, Refractory Nodular Sclerosis Classical Hodgkin Lymphoma | 12/20 | 12/24 | | |
| Active, not recruiting | 2 | 110 | Europe, US, RoW | Parsaclisib, INCB050465 | Incyte Corporation | Lymphoma | 01/21 | 05/24 | | |
|
|
| Active, not recruiting | 2 | 126 | Europe, Canada, US, RoW | Parsaclisib, INCB050465 | Incyte Corporation | Lymphoma | 02/21 | 07/24 | | |
|
|
NCT00492050: Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia |
|
|
| Active, not recruiting | 2 | 46 | US | Bortezomib, Velcade, LDP-341, MLN341, PS-341, Rituximab, Rituxan, Valacyclovir, Valtrex | M.D. Anderson Cancer Center, Millennium Pharmaceuticals, Inc. | Waldenstrom's Macroglobulinemia | 02/21 | 06/24 | | |
| Completed | 2 | 162 | Europe, US, RoW | Parsaclisib, INCB050465 | Incyte Corporation | Lymphoma | 03/21 | 04/24 | | |
|
|
2020-002324-36: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies |
|
|
| Not yet recruiting | 2 | 450 | Europe, RoW | MK-1026, [-], Tablet | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC | B cell malignancies: Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters transformation; Mantle cell lymphoma, Marginal zone lymphoma; Follicular lymphoma; Waldenstroms macroglobulinemia, Diseases [C] - Cancer [C04] | | | | |
PARCT, NCT03357224: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) |
|
|
| Terminated | 2 | 26 | Europe | Atezolizumab, Tecentriq | European Organisation for Research and Treatment of Cancer - EORTC, Hoffmann-La Roche | Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome | 03/21 | 08/22 | | |
2018-001850-80: Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma |
|
|
| Not yet recruiting | 2 | 80 | Europe | acalabrutinib, Mabthera, Capsule, hard, Concentrate for solution for infusion, Mabthera | Skåne University Hospital, Nordic Lymphoma Group, Astra Zeneca | Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma (MCL), Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2019-001073-86: A study of MT-3724 investigational drug for the treatment of patients with resistant or recurring B-cell cancer |
|
|
| Not yet recruiting | 2 | 108 | Europe, RoW | MT-3724, Concentrate for solution for infusion | Molecular Templates, Inc., Molecular Templates, Inc. | relapsed or refractory diffuse large B-cell lymphoma (DLBCL), relapsed or refractory lymphoma, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 25 | Japan | Valemetostat Tosylate, DS-3201b | Daiichi Sankyo Co., Ltd. | Adult T-cell Leukemia/Lymphoma | 04/21 | 12/25 | | |
NCT04470141: A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma |
|
|
| Not yet recruiting | 2 | 130 | NA | SHC014748M treatment | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Peripheral T Cell Lymphoma | 05/21 | 07/21 | | |
2020-004910-37: Study to compare the efficacy and safety of the combinaison of venetoclax+ibrutinib in patients with untreated mantle cell lymphoma |
|
|
| Not yet recruiting | 2 | 194 | Europe | ibrutinib, venetoclax, ABT - 199, Capsule, hard, Tablet, Imbruvica, Venclyxto | LYSARC, Janssen Pharmaceutica NV, Abbvie Inc | Untreated mantle cell lymphoma, Untreated mantle cell lymphoma, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 42 | Europe, US, RoW | Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide | Kite, A Gilead Company | B-cell Lymphoma | 05/21 | 10/23 | | |
|
|
|
2020-005609-20: Study of Pembroliumab Given Every Six Weeks to Participants with rrcHL or rrPMBCL Klinické hodnocení fáze 2 zkoumající léčbu rrcHL nebo rrPMBCL přípravkem MK-3475 podávaným jednou za 6 týdnů |
|
|
| Not yet recruiting | 2 | 60 | RoW, Europe | -, MK-3475, Solution for infusion, KEYTRUDA® (Pembrolizumab, MK-3475) | Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or refractory Primary Large B-cell Lymphoma, Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or refractory Primary Large B-cell, Diseases [C] - Cancer [C04] | | | | |
2020-004409-30: Treatment with venetoclax consolidated with ibrutinib and rituximab to increase the possibility of minimal residual disease in patient with chronic lymphotic leukemia Trattamento con venetoclax consolidato con ibrutinib e rituximab per aumentare possibilità di malattia minima residua in paziente con leucemia linfatica cronica |
|
|
| Not yet recruiting | 2 | 55 | Europe | venclyxto, [venclyxto], Modified-release tablet, Venclyxto | OSPEDALE SAN RAFFAELE, AbbVie | Previously Untreated Chronic Lymphophatic Leukaemia Leucemia Linfatica Cronica non precedentemente trattata, Previously untreated low-risk blood cancer Tumore del sangue a basso rischio, non precedentemente trattato, Diseases [C] - Cancer [C04] | | | | |
2021-000311-23: Ibrutinib and Obinutuzumab as first-line treatment for patients with Chronic Lymphocytic Leukemia Ibrutinib e Obinutuzumab come trattamento di prima linea per pazienti affetti dalla Leucemia Linfatica Cronica |
|
|
| Not yet recruiting | 2 | 53 | Europe | NA, Gazyvaro, [NA], [Gazyvaro], Capsule, hard, Concentrate for solution for injection, imbruvica, gazyvaro | OSPEDALE SAN RAFFAELE, Janssen-Cilag International N.V., Belgium | chronic lymphocytic leukemia/small lymphocytic lymphoma Leucemia Linfatica Cronica/ Linfoma linfocitico a piccole cellule, chronic lymphocytic leukemia/small lymphocytic lymphoma Leucemia Linfatica Cronica/ Linfoma linfocitico a piccole cellule, Diseases [C] - Cancer [C04] | | | | |
2019-004396-38: Clinical study of acalabrutinib and tafasitamab in previously treated marginal zone lymphoma |
|
|
| Not yet recruiting | 2 | 24 | Europe | Acalabrutinib, Tafasitamab, MOR00208, Capsule, hard, Powder and solvent for concentrate for solution for infusion, Minjuvi | IELSG - International Extranodal Lymphoma Study Group, IELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP, Astra Zeneca AG, Incyte Bioseciences International Sàrl, Incyte Biosciences International Sàrl, AstraZeneca AG | Marginal Zone Lymphomas refractory to or in first or greater relapse after prior systemic therapy, Previously treated marginal zone lymphomas, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 9 | US | Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475 | University of Washington, Merck Sharp & Dohme LLC | Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma | 06/21 | 04/26 | | |
2020-005546-42: Sentinel lymph node assessment in ovarian cancer. Lymphatic mapping with two tracers and intraoperative lymphoscintigraphy. Evaluación del ganglio centinela en el cáncer de ovario. Estudio del mapa linfático con dos trazadores y gammagrafía intraoperatoria. |
|
|
| Ongoing | 2 | 62 | Europe | Powder for injection, Verdye, Nanocoloides de albúmina Radiopharmacy | Fundacio Clinic per a la Recerca Biomedica, Hospital Clinic Barcelona | Sentinel lymph node in ovarian cancer Ganglio centinela en cáncer de ovario, Sentinel lymph node in ovarian cancer Ganglio centinela en cáncer de ovario, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | | | | |
2020-005515-51: Tamoxifen and Venetoclax in R/R DLBCL Tamoxifen en Venetoclax in R/R DLBCL |
|
|
| Ongoing | 2 | 6 | Europe | Film-coated tablet, Venclyxto, Tamoxifen | Medical University Medical Center Groningen, University Medical Center Groningen | relapsed/refractory Diffuse Large B-cell Lymphoma recidiverend / refractair diffuus grootcellig B-cellymfoom, lymphoma lymfoom kanker, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT03800706: A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 85 | RoW | TQB2450 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Safety and Effectiveness | 06/21 | 12/21 | | |
NCT01574274: SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma |
|
|
| Active, not recruiting | 2 | 240 | Canada, US | SC-PEG, Oncaspar | Dana-Farber Cancer Institute, Shire, National Cancer Institute (NCI) | Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | 07/21 | 07/27 | | |
